Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.
Paolo F. Caimi, MD
Advertisement
Articles by Paolo F. Caimi, MD
Paolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine-lpyl in relapsed/refractory large B-cell lymphoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
5